You've Had Tests Done. But Nobody's Looked at Your Genes.

BRCA1 is one of your cell’s primary DNA repair systems. Every time a cell divides, its DNA gets copied. That process introduces errors. BRCA1 patrols for those errors and fixes them. Without a working BRCA1, damaged DNA accumulates in your cells unchecked.

BRCA1 variants are carried by roughly 1 in 400 people. When you carry a pathogenic variant, your cells lose the ability to repair DNA double-strand breaks, allowing mutations to accumulate and eventually trigger cancer. The lifetime risk for breast cancer with a BRCA1 variant is 55-72%. For ovarian cancer, it’s roughly 40-50%.

What this means in real life: if you’re a woman with a BRCA1 variant, you’re looking at needing earlier and more frequent mammograms, potentially prophylactic surgery, and genetic counseling before having children. If you’re a man with a BRCA1 variant, your breast cancer risk is elevated, though less dramatically than for women.

BRCA2 is BRCA1’s partner. It works alongside BRCA1 to coordinate DNA repair when cells divide. A BRCA2 variant means the same problem: unrepaired DNA damage accumulating in your cells over time.

BRCA2 variants are carried by roughly 1 in 800 people. When you carry a pathogenic BRCA2 variant, your lifetime breast cancer risk is 45-69%, and your ovarian cancer risk climbs to roughly 20-30%. Men with BRCA2 variants face elevated breast cancer risk (6-8% lifetime) and elevated prostate cancer risk.

The difference between BRCA1 and BRCA2: while BRCA1 predominantly affects women, BRCA2 also notably elevates male breast cancer risk and other cancers including pancreatic. For men, this matters. If your family has male breast cancer or pancreatic cancer in addition to female breast cancer, BRCA2 becomes the more likely culprit.

MTHFR converts folate into methylfolate, the activated form your cells use to build DNA and regulate homocysteine. When MTHFR carries the C677T variant, this conversion becomes sluggish.

Roughly 40% of people of European ancestry carry the C677T variant. This variant reduces MTHFR enzyme efficiency by 40-70%, meaning homocysteine accumulates in your bloodstream even if your folate levels appear normal on bloodwork. Elevated homocysteine is an independent cardiovascular risk factor; it’s linked to higher rates of heart attack, stroke, and clotting disorders.

What this means day-to-day: you might see elevated homocysteine on a comprehensive metabolic panel and be told to take folic acid supplements. But if you have an MTHFR variant, you can’t convert folic acid efficiently. Your homocysteine stays elevated. Your cardiovascular risk stays elevated. Nobody connects the dots because they’re not looking at your gene.

Factor V is a protein that helps your blood clot. It’s essential when you’re bleeding. It becomes dangerous when it’s too active or when you can’t turn it off efficiently. The Factor V Leiden variant (R506Q) makes Factor V resistant to the protein that normally shuts it down.

Roughly 5% of people of European ancestry carry Factor V Leiden. This variant increases your venous thromboembolism risk (blood clots in veins) by 4-8 fold. If you’re a woman taking oral contraceptives with this variant, your clot risk jumps 80-fold. If you’re immobilized (surgery, long flight, hospitalization), your clot risk is significantly elevated.

What this means in real life: a clot in your leg (deep vein thrombosis) can break free and lodge in your lungs (pulmonary embolism). That’s a medical emergency. If you don’t know you carry Factor V Leiden and you take oral contraceptives, you’re running this risk unknowingly every day. If you need surgery and aren’t on anticoagulant prophylaxis, you’re running this risk.

HBB encodes beta-globin, the protein that sits inside red blood cells and carries oxygen. When HBB carries certain variants (like the sickle mutation), hemoglobin molecules distort under low oxygen, and red blood cells become rigid and sickle-shaped. This causes pain, organ damage, and early death without treatment.

Beta-thalassemia variants are carried by roughly 1 in 1,000 to 1 in 10,000 people depending on ancestry (much more common in Mediterranean, Middle Eastern, and Asian populations). If both you and your partner carry a beta-thalassemia variant, each child has a 25% chance of inheriting both copies and developing severe beta-thalassemia major. If you’re a carrier of sickle cell, each child has a 50% chance of being a carrier.

What this means in real life: if you’re planning pregnancy and you carry an HBB variant, your partner needs testing. If you’re a carrier and your partner is also a carrier, genetic counseling becomes essential. Modern prenatal testing and in-vitro genetic selection can prevent affected pregnancies. If you’re unaware of carrier status, you cannot make informed reproductive choices.

HLA-DQ2 is part of your immune system’s identification system. It displays proteins to your immune cells to determine if they’re friend or foe. In people with the HLA-DQ2 variant, the immune system misidentifies gluten as a threat. It attacks the intestinal lining, triggering an autoimmune response.

Roughly 30-40% of the general population carries HLA-DQ2. Carrying HLA-DQ2 is necessary but not sufficient for celiac disease; you need both the gene and environmental trigger (gluten exposure) plus a third factor we don’t fully understand yet. About 3-5% of people who carry HLA-DQ2 actually develop celiac disease.

What this means day-to-day: if you carry HLA-DQ2, you’re at elevated risk for celiac disease, but you’re not destined to develop it. Knowing your HLA-DQ2 status helps you interpret digestive symptoms in context. If you carry it and develop unexplained GI symptoms, celiac testing becomes the obvious next step rather than ruling it out because it ‘seems unlikely.’